Perbandingan Efektivitas Kombinasi OHO (Obat Hipoglikemik Oral) Terhadap Gula Darah Puasa Pasien Diabetes Melitus Tipe 2 Comparison of the Effectiveness of Oral Hypoglycemic Agents (OHO) on Fasting Blood Glucose Levels in Type 2 Diabetes Mellitus Patients

Talitha Elliora Salsabilla; Zulfachmi Wahab; Yanuarita Tursinawati

doi:10.31004/koloni.v5i2.966

Authors

Talitha Elliora Salsabilla Universitas Muhammadiyah Semarang
Zulfachmi Wahab Universitas Muhammadiyah Semarang
Yanuarita Tursinawati Universitas Muhammadiyah Semarang

DOI:

https://doi.org/10.31004/koloni.v5i2.966

Keywords:

Type 2 Diabetes Mellitus, Fasting Blood Glucose, Metformin, Gliclazide, Glimepiride

Abstract

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease characterized by insulin resistance and impaired insulin secretion, leading to increased blood glucose levels. Optimal blood glucose control is necessary to prevent long-term complications. One of the parameters used to assess glycemic control is Fasting Blood Glucose (FBS). This study aims to compare the effectiveness of the combination of metformin-glimepiride and metformin-gliclazide on FBS levels in T2DM patients. This study is a quantitative, observational, and analytical study using a cross-sectional approach. Data were obtained from the medical records of outpatients with T2DM at K.R.M.T. Wongsonegoro Regional General Hospital from January 2022 to December 2023. The study sample consisted of 50 patients selected using a purposive sampling technique, consisting of 25 patients receiving metformin-glimepiride therapy and 25 patients receiving metformin-gliclazide therapy. Data analysis was performed using the Paired T-Test, Mann–Whitney, and Independent T-Test. The results showed that both therapy combinations resulted in significant reductions in GDP after three months of therapy. The Mann–Whitney test showed no significant difference in GDP reduction between the two groups. However, the Independent T-Test showed a significant difference in final GDP levels, with the metformin-gliclazide group having a lower mean final GDP than the metformin-glimepiride group. Therefore, the metformin-gliclazide combination is superior in controlling GDP levels in patients with type 2 diabetes compared to the metformin-glimepiride combination.

References

Al-Omary, F. A. M. (2017). Chapter Three – Gliclazide. Profiles of Drug Substances, Excipients and Related Methodology, 42, 125–192.

Anilasree, B. P., Sreekumar, S., Nazeer, N., Husna, P., Azeez, R. B. A., & Basheer, N. (2019). Drug Utilization Evaluation of Anti Diabetic Therapy with Type-II Diabetes Mellitus of a Tertiary Care Hospital in Calicut. Journal of Medical Pharmaceutical and Allied Sciences, 8(3), 2235–2353.

Arini, N. M. A., & Dwipayana, I. M. P. (2020). Hubungan Kadar HbA1c terhadap Terapi Obat Anti Diabetes Oral dan Kombinasi Obat Anti Diabetes Oral-Insulin pada Penderita DM Tipe 2 di Poliklinik Diabetes RSUP Sanglah Denpasar Tahun 2016. Jurnal Medika Udayana, 9(9), 94–98.

Chaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., et al. (2018). The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metabolism, 28(3), 337–352.

Chia, C. W., Egan, J. M., & Ferrucci, L. (2018). Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. Circulation Research, 123(7), 886–904.

Cornell, S. (2015). Continual Evolution of Type 2 Diabetes: An Update on Pathophysiology and Emerging Treatment Options. Therapeutics and Clinical Risk Management, 11, 621–632.

Defirson, L. A. (2021). Perbandingan Efektivitas Obat Antidiabetik Oral pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan di Rumah Sakit “X” Kota Jambi. Riset Informasi Kesehatan, 10(2), 134–142.

Dinas Kesehatan Jawa Tengah. (2021). Profil Kesehatan Jawa Tengah Tahun 2021. Semarang: Dinas Kesehatan Provinsi Jawa Tengah.

Galaviz, K. I., Narayan, K. M. V., Lobelo, F., & Weber, M. B. (2018). Lifestyle and the Prevention of Type 2 Diabetes: A Status Report. American Journal of Lifestyle Medicine, 12(1), 4–20. https://doi.org/10.1177/1559827615619159

Gumantara, M. P. B., & Oktarlina, R. Z. (2017). Perbandingan Monoterapi dan Kombinasi Terapi Sulfonilurea-Metformin terhadap Pasien Diabetes Melitus Tipe 2. Jurnal Majority, 6(1), 55–59.

Gunawan, S., & Rahmawati, R. (2021). Hubungan Usia, Jenis Kelamin dan Hipertensi dengan Kejadian Diabetes Mellitus Tipe 2 di Puskesmas Tugu Kecamatan Cimanggis Kota Depok Tahun 2019. ARKESMAS (Arsip Kesehatan Masyarakat), 6(1), 15–22.

Harrower, A. (2000). Gliclazide Modified Release: From Once-Daily Administration to 24-Hour Blood Glucose Control. Metabolism, 49(10), 7–11.

Hassan, M. H., & Abd-Allah, G. M. (2015). Effects of Metformin Plus Gliclazide Versus Metformin Plus Glimepiride on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus. Pakistan Journal of Pharmaceutical Sciences, 28(5), 1723–1730.

Ibrahim, M., Munir, S., Ahmed, S., Chughtai, A. H., Ahmad, W., Khan, J., et al. (2022). Gliclazide in Binary and Ternary Systems Improves Physicochemical Properties, Bioactivity, and Antioxidant Activity. Oxidative Medicine and Cellular Longevity, 2022, Article 3586245. https://doi.org/10.1155/2022/3586245

Imelda, S. I. (2019). Faktor-Faktor yang Mempengaruhi Terjadinya Diabetes Melitus di Puskesmas Harapan Raya Tahun 2018. Scientific Journal, 8(1), 28–39.

Jonathan, K., & Soetedjo, N. M. (2019). Pola Penggunaan Antidiabetes Oral Pasien Diabetes Melitus Tipe 2 di Bagian Penyakit Dalam RSUD Kota Bandung Tahun 2017. Jurnal Cermin Dunia Kedokteran, 46(6), 407–413.

Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., et al. (2018). Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism, 22(1), 132–157.

Katakami, N., & Hori, M. (2004). Metformin or Gliclazide, Rather than Glibenclamide, Attenuate Progression of Carotid Intima-Media Thickness in Subjects with Type 2 Diabetes. Diabetologia, 47, 1906–1913.

Katzung, B. G., Masters, S. B., & Trevor, A. J. (2013). Farmakologi Dasar dan Klinik (Edisi ke-12). Jakarta: EGC.

Kementerian Kesehatan Republik Indonesia. (2020). Infodatin: Tetap Produktif, Cegah, dan Atasi Diabetes Melitus 2020. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI.

Kementerian Kesehatan Republik Indonesia. (2021). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa. Jakarta: Kementerian Kesehatan Republik Indonesia.

Khunti, K., & Hassanein, M. (2020). Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy, 11(Suppl. 2), 33–48.

Made, P., Ratnasari, D., Kurnianta, D. M., Yuliawati, A. N., et al. (2022). Penggunaan Obat pada Pasien Diabetes Melitus Tipe 2 Disertai Dislipidemia di Rumah Sakit X Denpasar. Jurnal Ilmiah Mahaganesha, 1(2).

Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. del. (2016). Update on the Treatment of Type 2 Diabetes Mellitus. World Journal of Diabetes, 7(17), 354–395.

Meidikayanti, W., & Wahyuni, C. U. (2017). Hubungan Dukungan Keluarga dengan Kualitas Hidup Diabetes Melitus Tipe 2 di Puskesmas Pademawu. Jurnal Berkala Epidemiologi, 5(2), 240–252.

Mulyati, S. (2016). Peranan Advanced Glycation End-Products pada Diabetes. Jurnal Cermin Dunia Kedokteran, 43(6), 422–426.

Norhalimah, N., Agustina, R., & Rusli, R. (2018). Analisis Biaya Minimal dan Efektivitas Terapi Diabetes Melitus Tipe 2 di RSUD Panglima Sebaya Paser. Proceeding Mulawarman Pharmaceutical Conference, 7, 63–69.

Rahaman, M., Das, A., Ray, S., Islam, T., Akther, N., Ansari, M. J., et al. (2023). Effects on Glycemic Control by Combination Therapy of Gliclazide-Metformin and Insulin in Type 2 Diabetes Mellitus Patients. Bangladesh Journal of Endocrinology and Metabolism, 2(1), 51.

Rodrigues, P. A., Aathira, U. K., Varshini, V., P. L. J., & Shuruthi, S. (2020). Comparison of Efficacy and Safety of Sulphonylureas-Glimepiride or Gliclazide in Combination with Metformin in Type 2 Diabetes Mellitus Patients. International Journal of Pharmacy and Pharmaceutical Research, 19(3), 67–82.

Rojanasthien, N., Autsavakitipong, T., Kumsorn, B., Manorot, M., & Teekachunhatean, S. (2012). Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers. ISRN Pharmacology, 2012, Article 375926. https://doi.org/10.5402/2012/375926

Rosita, R., Kusumaningtiar, D. A., Irfandi, A., & Ayu, I. M. (2022). Aktivitas Fisik Lansia dengan Diabetes Melitus Tipe 2 di Puskesmas Balaraja Kabupaten Tangerang. Jurnal Kesehatan Masyarakat, 10(3), 364–371.

Serri, O., & Renier, G. (1999). Gliclazide Reduces the Induction of Human Monocyte Adhesion to Endothelial Cells by Glycated Albumin. Diabetes, Obesity and Metabolism, 1, 113–120.

Singh, A. K., & Singh, R. (2016). Is Gliclazide a Sulfonylurea with Difference? A Review in 2016. Expert Review of Clinical Pharmacology, 9(6), 839–851.

Soelistijo, S., Suastika, K., Lindarto, D., et al. (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Jakarta: PB PERKENI.

Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., et al. (2015). Sulfonylureas and Their Use in Clinical Practice. Archives of Medical Science, 11(4), 840–848.

Stubbs, D. J., Levy, N., & Dhatariya, K. (2017). Diabetes Medication Pharmacology. BJA Education, 17(6), 198–207.

Tjandrawinata, R. (2016). Patogenesis Diabetes Tipe 2: Resistensi dan Defisiensi Insulin. Jakarta: Dexa Laboratories of Biomolecular Science.